Viking Therapeutics, Inc.
VKTX
$24.99
-$0.67-2.61%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -36.83% | -28.02% | -22.64% | -30.58% | -29.64% |
| Total Depreciation and Amortization | 30.27% | 18.49% | 6.90% | -17.55% | 2.80% |
| Total Amortization of Deferred Charges | 2.27% | 6.82% | 37.14% | -22.11% | 17.33% |
| Total Other Non-Cash Items | 45.98% | 44.00% | 30.58% | -4.76% | 4.72% |
| Change in Net Operating Assets | -177.59% | 163.87% | 172.09% | 380.76% | 4,277.10% |
| Cash from Operations | -144.20% | -19.64% | -11.38% | -18.91% | 12.23% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 95.27% | -208.99% | -152.56% | -234.65% | -1,258.60% |
| Cash from Investing | 95.27% | -208.99% | -152.56% | -234.65% | -1,258.60% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -99.26% | 134.97% | 125.29% | 124.41% | 5,063.03% |
| Repurchase of Common Stock | 100.00% | -485.14% | -411.62% | -417.17% | -976.03% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | 162.71% |
| Cash from Financing | -99.22% | 125.69% | 116.95% | 115.96% | 6,439.57% |
| Foreign Exchange rate Adjustments | -43.48% | -393.33% | -139.34% | 32.98% | 74.16% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -188.95% | -252.72% | 69.24% | -148.04% | 2,899.61% |